Gapping up
In reaction to strong earnings/guidance:
- CLDR +6.4%, EXPR +4%, UNFI +1.5%, MEET +1%
Other news:
- INO +23.3% (continued volatility after closing lower by 42%)
- DXC +13.3% (to sell US State & Local HHS business for $5.0 bln; also withdrew previously provided forecast estimates for FY22)
- NCNA +8.7% (reported preliminary data from Phase II study of Acelarin in patients with platinum-resistant ovarian cancer)
- KMDA +7.3% (plans to initiate the development of an Anti-Corona (COVID-19) polyclonal immunoglobulin using its proprietary plasma derived IgG platform technology as a potential treatment for severely ill coronavirus patients)
- STNG +7.1% (announced purchase of call options by President Robert Bugbee)
- RDHL +6.9% (provided an update on its clinical development programs for opaganib)
- PRTK +6.6% (submitted pre-emergency use authorization for NUZYRA to FDA)
- MNK +5.9% (announces that New York State Attorney General Letitia James has joined 47 other state and U.S. Territory Attorneys General in supporting the previously announced proposed global opioid settlement with Mallinckrodt and related entities)
- KALA +5.8% (prices offering of 16,000,000 shares of its common stock at $7.89/share)
- GILD +2.7% (continued volatility in relation to COVID-19)
- STWD +1.1% (authorizes $400 mln stock repurchase)
Analyst comments:
- ZUMZ +1.9% (upgraded to Neutral from Underperform at Wedbush)
- ANF +1.3% (upgraded to Outperform from Neutral at Wedbush)
- SPR +1.1% (upgraded to Buy from Neutral at Goldman)